VRTX Share Price

Open 153.59 Change Price %
High 155.11 1 Day -0.41 -0.27
Low 151.79 1 Week -3.62 -2.31
Close 153.20 1 Month 5.07 3.42
Volume 1290101 1 Year 61.94 67.87
52 Week High 167.85
52 Week Low 71.46
VRTX Important Levels
Resistance 2 156.28
Resistance 1 155.01
Pivot 153.37
Support 1 151.39
Support 2 150.12
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
SCHS 0.04 33.33%
ZAZA 0.04 33.33%
GCFB 0.50 31.58%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VRTX Technical Analysis 4
As on 18th Sep 2017 VRTX Share Price closed @ 153.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 109.58 & Buy for SHORT-TERM with Stoploss of 150.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRTX Target for September
1st Target up-side 167.99
2nd Target up-side 173.21
3rd Target up-side 178.43
1st Target down-side 153.09
2nd Target down-side 147.87
3rd Target down-side 142.65
VRTX Other Details
Segment EQ
Market Capital 9959515136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vrtx.com
VRTX Address
VRTX
50 Northern Avenue
Boston, MA 02210
United States
Phone: 617-341-6100
VRTX Latest News
Interactive Technical Analysis Chart Vertex Pharmaceuticals Incorporated ( VRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vertex Pharmaceuticals Incorporated
VRTX Business Profile
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.